Rani Non Operating Income Net Other from 2010 to 2026
| RANI Stock | USD 1.34 0.04 2.90% |
Non Operating Income Net Other | First Reported 2010-12-31 | Previous Quarter 1.1 M | Current Value 998.4 K | Quarterly Volatility 66 K |
Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.3 M, Depreciation And Amortization of 742.1 K or Interest Expense of 6.1 M, as well as many indicators such as Price To Sales Ratio of 41.46, Dividend Yield of 0.0 or PTB Ratio of 18.51. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
Rani | Non Operating Income Net Other | Build AI portfolio with Rani Stock |
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out the analysis of Rani Therapeutics Correlation against competitors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is there potential for Biotechnology market expansion? Will Rani introduce new products? Factors like these will boost the valuation of Rani Therapeutics. Anticipated expansion of Rani directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Rani Therapeutics requires distinguishing between market price and book value, where the latter reflects Rani's accounting equity. The concept of intrinsic value—what Rani Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Rani Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Rani Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rani Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Rani Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.